US Patent 11919921 Galactoside inhibitor of galectins
Patent 11919921 was granted and assigned to Galecto Biotech on March, 2024 by the United States Patent and Trademark Office.
All edits
Edits on 12 Mar, 2024
Golden AI
Edits made to:
Infobox (+20 properties)
Article (+476 characters)
US Patent 11919921 Galactoside inhibitor of galectins
Article
Patent abstract
An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Patent Inventor Names
Fredrik Zetterberg0
Hakon Leffler0
Richard Johnsson0
Thomas Brimert0
Ulf Nilsson0
Date of Patent
March 5, 2024
0Patent Application Number
177483380
Date Filed
May 19, 2022
0Patent Citations
Patent Primary Examiner
Find more entities like US Patent 11919921 Galactoside inhibitor of galectins
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.